Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection unde…
Biotechnology
US, San Francisco [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -154.61 | -27.66 | -10.87 | |
| Graham Fair Price | -26.36 | 11.14 | 15.13 | |
| PEG | 20.90 | 0.12 | 0.10 | |
| Price/Book | 4.72 | 0.89 | 0.85 | |
| Price/Cash Flow | -0.25 | -12.40 | -12.37 | |
| Prices/Earnings | -81.04 | -5.28 | -2.92 | |
| Price/Sales | -69.66 | 24.48 | 80.67 | |
| Price/FCF | -0.25 | -12.40 | -12.37 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | 34.01 | 0.92 | 0.69 | |
| Operating Margin | 86.66 | -0.93 | -6.98 | |
| ROA | 38.50 | -0.04 | -0.06 | |
| ROE | -0.07 | -0.04 | 42.15 | |
| ROIC | -0.07 | -0.03 | 51.84 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.03 | 0.09 | -69.61 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.37 | 0.55 | 48.03 | |
| EPS QOQ | 0.30 | 0.44 | 49.74 | |
| FCF QOQ | 0.31 | -0.02 | -94.76 | |
| Revenue QOQ | 5.10 | 2.36 | -53.73 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Balanced
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 62.19 | 15.64 | -74.84 | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | 0.07 | 0.07 | -0.07 | |
| Quick Ratio | 8.82 | 12.47 | 41.35 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 11.81 | 11.44 | -3.18 | |
| Cash | 11.41 | 8.60 | -24.64 | |
| Capex | -0.01 | -0.01 | -21.35 | |
| Free Cash Flow | -0.81 | -0.82 | -1.14 | |
| Revenue | 0.12 | 0.42 | 234.16 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad